<table border="0" cellpadding="0" cellspacing="0" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Omeprazole and Interaction with Diagnostics</caption>
<colgroup>
<col width="20%"></col>
<col width="80%"></col>
</colgroup>
<tbody>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Antiretrovirals</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.<br/> <br/>
<list listtype="unordered" stylecode="disc">
<item>Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance <content stylecode="italics">[see <linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>].</content>
</item>
</list>
<list listtype="unordered" stylecode="disc">
<item>Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with omeprazole may increase toxicity <content stylecode="italics">[see <linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>].</content>
</item>
</list>
<list listtype="unordered" stylecode="disc">
<item>There are other antiretroviral drugs which do not result in clinically relevant interactions with omeprazole.<content stylecode="bold"></content>
</item>
</list>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="underline">Rilpivirine-containing products:</content> Concomitant use with omeprazole is contraindicated <content stylecode="italics">[see <content stylecode="underline">
<linkhtml href="#Section_4">Contraindications (4)</linkhtml>
</content>]</content>.<br/> <br/>
<content stylecode="underline">Atazanavir:</content> Avoid concomitant use with omeprazole. See prescribing information for atazanavir for dosing information.<br/> <br/>
<content stylecode="underline">Nelfinavir:</content> Avoid concomitant use with omeprazole. See prescribing information for nelfinavir.<br/> <br/>
<content stylecode="underline">Saquinavir:</content> See the prescribing information for saquinavir for monitoring of potential saquinavir-related toxicities.<br/> <br/>
<content stylecode="underline">Other antiretrovirals:</content> See prescribing information for specific antiretroviral drugs.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Warfarin</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Increased INR and prothrombin time in patients receiving PPIs, including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">         Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Monitor INR and prothrombin time and adjust the dose of warfarin, if needed, to maintain target INR range.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Methotrexate</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant use of omeprazole with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities. No formal drug interaction studies of high-dose methotrexate with PPIs have been conducted <content stylecode="italics">[see <content stylecode="underline">
<linkhtml href="#Section_5.18">Warnings and Precautions (5.11)</linkhtml>
</content>].</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">A temporary withdrawal of omeprazole may be considered in some patients receiving high-dose methotrexate.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol, phenytoin, diazepam)</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Clopidogrel</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition <content stylecode="italics">[see <content stylecode="underline">
<linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>
</content>].</content>
<br/>There are no adequate combination studies of a lower dose of omeprazole or a higher dose of clopidogrel in comparison with the approved dose of clopidogrel<content stylecode="italics">.</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">        Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Avoid concomitant use with omeprazole. Consider use of alternative anti-platelet therapy <content stylecode="italics">[see <content stylecode="underline">
<linkhtml href="#Section_5.20">Warnings and Precautions (5.6)</linkhtml>
</content>].</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Citalopram</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Increased exposure of citalopram leading to an increased risk of QT prolongation <content stylecode="italics">[see <content stylecode="underline">
<linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>
</content>]</content>.<content stylecode="italics"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">         Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Limit the dose of citalopram to a maximum of 20 mg per day. See prescribing information for citalopram.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Cilostazol</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="center" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Increased exposure of one of the active metabolites of cilostazol (3,4-dihydro-cilostazol) <content stylecode="italics">[see <content stylecode="underline">
<linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>
</content>].</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="center" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">          Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Reduce the dose of cilostazol to 50 mg twice daily. See prescribing information for cilostazol.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Phenytoin</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Potential for increased exposure of phenytoin.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="center" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">         Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Monitor phenytoin serum concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for phenytoin.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Diazepam</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"></td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Increased exposure of diazepam <content stylecode="italics">[see <content stylecode="underline">
<linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>
</content>]</content>.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Monitor patients for increased sedation and reduce the dose of diazepam as needed.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Digoxin</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Potential for increased exposure of digoxin <content stylecode="italics">[see <content stylecode="underline">
<linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>
</content>].</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Monitor digoxin concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See digoxin prescribing information.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole)</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Mycophenolate mofetil (MMF): Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving omeprazole and MMF. Use omeprazole with caution in transplant patients receiving MMF <content stylecode="italics">[see <content stylecode="underline">
<linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>
</content>]</content>.<br/> <br/>See the prescribing information for other drugs dependent on gastric pH for absorption.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Combination Therapy with Clarithromycin and Amoxicillin</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions, including potentially fatal arrhythmias, and are contraindicated. Amoxicillin also has drug interactions.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">See <content stylecode="italics">
<content stylecode="underline">
<linkhtml href="#Section_4">Contraindications</linkhtml>
</content>
</content>
<content stylecode="italics">, </content>
<content stylecode="italics">
<content stylecode="underline">
<linkhtml href="#Section_5">Warnings  and  Precautions</linkhtml>
</content>
</content>
<content stylecode="italics">  </content>in prescribing information for clarithromycin.<br/> <br/>See <content stylecode="italics">
<content stylecode="italics">
<content stylecode="underline">
<linkhtml href="#Section_7">Drug Interactions</linkhtml>
</content>
</content>  </content>in prescribing information for amoxicillin.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Tacrolimus</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Potential for increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19<content stylecode="italics">.</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Monitor tacrolimus whole blood concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for tacrolimus.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Interactions with Investigations of Neuroendocrine Tumors</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Serum chromogranin A (CgA) levels increase secondary to PPI-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors <content stylecode="italics">[see <content stylecode="italics">
<content stylecode="underline">
<linkhtml href="#Section_5.17">Warnings and Precautions (5.10)</linkhtml>
</content>
</content>, <content stylecode="italics">
<content stylecode="underline">
<linkhtml href="#Section_12.2">Clinical Pharmacology (12.2)</linkhtml>
</content>
</content>]</content>.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Temporarily stop omeprazole treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Interaction with Secretin Stimulation Test</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Temporarily stop omeprazole treatment at least 14 days before assessing to allow gastrin levels to return to baseline <content stylecode="italics">[see Clinical Pharmacology (12.2)]</content>.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">False Positive Urine Tests for THC</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">An alternative confirmatory method should be considered to verify positive results.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Other</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram).<br/>
</td>
</tr>
<tr>
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Monitor patients to determine if it is necessary to adjust the dosage of these other drugs when taken concomitantly with omeprazole.<br/>
</td>
</tr>
</tbody>
</table>